Prot #CYTB323J12201: A Phase 2, Adaptive, Randomized, Open-Label, Assessor-Blinded Active-Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Standard of Care in Patients Suffering from Systemic Lupus Erythematosus (SL

Project: Research project

Project Details

StatusActive
Effective start/end date3/19/24 → 12/31/30

Funding

  • Novartis Pharmaceuticals Corporation (Prot #CYTB323J12201)